412 related articles for article (PubMed ID: 35645791)
1. Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?
Budgett RF; Bakker G; Sergeev E; Bennett KA; Bradley SJ
Front Pharmacol; 2022; 13():893422. PubMed ID: 35645791
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?
Spampinato SF; Copani A; Nicoletti F; Sortino MA; Caraci F
Front Mol Neurosci; 2018; 11():414. PubMed ID: 30483053
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease.
Williams CJ; Dexter DT
J Neurochem; 2014 Apr; 129(1):4-20. PubMed ID: 24224472
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptors and neurodegenerative diseases.
Ribeiro FM; Vieira LB; Pires RG; Olmo RP; Ferguson SS
Pharmacol Res; 2017 Jan; 115():179-191. PubMed ID: 27872019
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation.
Carvalho TG; Alves-Silva J; de Souza JM; Real ALCV; Doria JG; Vieira ELM; Gomes GF; de Oliveira AC; Miranda AS; Ribeiro FM
Neurochem Int; 2019 Jun; 126():218-228. PubMed ID: 30930274
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases.
Rauf A; Badoni H; Abu-Izneid T; Olatunde A; Rahman MM; Painuli S; Semwal P; Wilairatana P; Mubarak MS
Molecules; 2022 May; 27(10):. PubMed ID: 35630670
[TBL] [Abstract][Full Text] [Related]
8. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?
Caraci F; Battaglia G; Sortino MA; Spampinato S; Molinaro G; Copani A; Nicoletti F; Bruno V
Neurochem Int; 2012 Sep; 61(4):559-65. PubMed ID: 22306345
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes.
Kwon HS; Koh SH
Transl Neurodegener; 2020 Nov; 9(1):42. PubMed ID: 33239064
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications.
Giri PM; Banerjee A; Ghosal A; Layek B
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612804
[TBL] [Abstract][Full Text] [Related]
12. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
Bian Y; Feng Z; Yang P; Xie XQ
AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.
Han J; Chitu V; Stanley ER; Wszolek ZK; Karrenbauer VD; Harris RA
Cell Mol Life Sci; 2022 Apr; 79(4):219. PubMed ID: 35366105
[TBL] [Abstract][Full Text] [Related]
14. "Selective" Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu
Hellyer SD; Albold S; Wang T; Chen ANY; May LT; Leach K; Gregory KJ
Mol Pharmacol; 2018 May; 93(5):504-514. PubMed ID: 29514854
[TBL] [Abstract][Full Text] [Related]
15. Preclinical translational platform of neuroinflammatory disease biology relevant to neurodegenerative disease.
Larson KC; Martens LH; Marconi M; Dejesus C; Bruhn S; Miller TA; Tate B; Levenson JM
J Neuroinflammation; 2024 Jan; 21(1):37. PubMed ID: 38297405
[TBL] [Abstract][Full Text] [Related]
16. Identification of monellin as the first naturally derived proteinaceous allosteric agonist of metabotropic glutamate receptor 5.
Chen ANY; Hellyer SD; Trinh PNH; Leach K; Gregory KJ
Basic Clin Pharmacol Toxicol; 2020 Jun; 126 Suppl 6():104-115. PubMed ID: 30983151
[TBL] [Abstract][Full Text] [Related]
17. Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators.
Gregory KJ; Velagaleti R; Thal DM; Brady RM; Christopoulos A; Conn PJ; Lapinsky DJ
ACS Chem Biol; 2016 Jul; 11(7):1870-9. PubMed ID: 27115427
[TBL] [Abstract][Full Text] [Related]
18. The brain as a target for inflammatory processes and neuroprotective strategies.
Skaper SD
Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
[TBL] [Abstract][Full Text] [Related]
19. Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis.
Paquet M; Ribeiro FM; Guadagno J; Esseltine JL; Ferguson SS; Cregan SP
Mol Brain; 2013 Feb; 6():9. PubMed ID: 23406666
[TBL] [Abstract][Full Text] [Related]
20. Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease.
Huang YY; Zhang Q; Zhang JN; Zhang YN; Gu L; Yang HM; Xia N; Wang XM; Zhang H
Brain Behav Immun; 2018 Jul; 71():93-107. PubMed ID: 29649522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
